Analytical and preanalytical issues in measurement of biochemical bone markers

Laboratory Medicine

Volumn 36, Issue 7, 2005, Pages 424-429

  Vesper, Hubert W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; CORTICOSTEROID; DEOXYPYRIDINOLINE; OSTEOCALCIN; PROCOLLAGEN; PYRIDINOLINE; TELOPEPTIDE;

ANALYTIC METHOD; ANOREXIA; BONE DENSITOMETRY; BONE DENSITY; BONE DISEASE; CANCER; FRACTURE; HUMAN; HYPERPARATHYROIDISM; HYPERTHYROIDISM; LACTATION; OSSIFICATION; OSTEOLYSIS; PREGNANCY; REVIEW; SEASON;

EID: 21744454495     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/GWQET8BDXQTUY83U     Document Type: Review

References (79)

1. 66 Federal Register 58843-58844 Medicare Program; Negotiated Rulemaking: Coverage and Administrative Policies for Clinical Diagnostic Laboratory Services; Final Rule. (Codified at 42 CFR §410). 2001.
2. Delmas PD. Biochemical markers of bone turnover. I: Theoretical considerations and clinical use in osteoporosis. Am J Med. 1993;95:S11-S16.
3. Delmas PD, Eastell R, Garnero P, et al. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteopor Int. 2000;11:S2-S17.
4. Eastell R. Biochemical markers of bone turnover in Paget's disease of bone. Bone. 1999;24:S49-S50.
5. Miller PD, Baran DT Bilezikian JP, et al. Practical clinical application of biochemical markers of bone turnover: Consensus of an expert panel. J Clin Densitom. 1999;2:323-342.
6. Nishizawa Y, Nakamura T, Ohata H, et al. Guidelines on the use of biochemical markers of bone turnover in osteoporosis. J Bone Miner Res. 2001;19:338-344.
7. Souberbielle JC, Cormier C, Kindermans C. Bone markers in clinical practice. Curr Opin Rheumatol. 1999;11:312-319.
8. Einhorn TA. The bone organ system. Form and function. In: Osteoporosis. Marcus R, Feldman D, Kelsey J, eds. San Diego, CA: Academic Press; 1995:3-21.
9. Garnero P, Delmas PD. An immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis. Bone. 2003;32:20-26.
10. Hart SM, Eastell R. Biochemical markers of bone turnover. Cur Opin Nephrol Hypert. 1999;8:421-427.
11. Eyre DR. Bone biomarkers as tools in osteoporosis management. Spine. 1997;22:S17-S24.
12. Garnero P, Delmas PD. Bone markers. Baillieres Clin Rheumatol. 1997;11:517-537.
13. Knott L, Bailey AJ. Collagen cross-links in mineralizing tissues: A review of their chemistry, function, and clinical relevance. Bone. 1998;22:181-187.
14. Robins SP. Collagen turnover in bone disease. Cur Opin Clin Nutr Metabol Care. 2003;6:65-71.
15. Russell RG. The assessment of bone metabolism in vivo using biochemical approaches. Horm Metab Res. 1997;29:138-144.
16. Delmas PD. Standardization of bone marker nomenclature. Clin Chem. 2001;47:1497.
17. CLSI. Application of biochemical markers of bone turnover in the assessment and monitoring of bone diseases; Approved Guideline. NCCLS Document C48-A, Wayne, PA. 2004.
18. Robins SP. Collagen crosslinks in metabolic bone disease. Acta Orthop Scan. 1995;266:S171-S175.
19. Robins SP, Black D, Paterson CR, et al. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. European J Clin Invest. 1991;21:310-315.
20. Robins SP, Duncan A, Wilson N, et al. Standardization of pyridinium crosslinks, pyridinoline and deoxypyridinoline, for use as biochemical markers of collagen degradation. Clin Chem. 1996;42:1621-1626.
21. Cloos PA, Fledelius C. Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: A biological clock of protein aging with clinical potential. Biochem J. 2000;345:473-480.
22. Cloos PA, Fledelius C, Christgau S, et al. Investigation of bone disease using isomerized and racemized fragments of type I collagen. Calc Tissue Int. 2003;72:8-17.
23. Garnero P, Gineyts E, Schaffer AV, et al. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthr Rheumat. 1998;41:354-360.
24. Garnero P, Cloos P, Sornay-Rendu E, et al. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: The OFELY prospective study. J Bone Miner Res. 2002;17:820-833.
25. Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Ann Clin Biochem. 2000;37:432-446.
26. Bruyere O, Collette J, Delmas P, et al. Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas. 2003;44:259-265.
27. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051-1056.
28. Garnero P, Sornay-Rendu E, Duboeuf F, et al. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: The OFELY study. J Bone Miner Res. 1999;14:1614-1621.
29. Garnero P, Mulleman D, Munoz F, et al. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: The OFELY study. J Bone Miner Res. 2003;18:1789-1794.
30. Hannon RA, Easrell R. Biochemical markers of bone turnover and fracture prediction. J Brit Menop Soc. 2003;9:10-15.
31. Johnell O, Oden A, De Laet C, et al. Biochemical indices of bone turnover and the assessment of fracture probability. Osteopor Internat. 2002;13:523-526.
32. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS Prospective Study. J Bone Miner Res. 1996;11:1531-1538.
33. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586-1592.
34. Bauer DC, Sklarin PM, Stone KL, et al. Biochemical markers of bone turnover and prediction of hip bone loss in older women: The study of osteoporotic fractures. J Bone Mine Res. 1999;14:1404-1410.
35. Chapurlat RD, Garnero P, Breart G, et al. Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: The EPIDOS study. Bone. 2000;27:283-286.
36. U.S. Department of Health and Human Services. Bone health and osteoporosis: A report of the surgeon general. U.S. Department of Health and Human Services, Office of the Surgeon General, 2004:209-217.
37. Looker AC, Bauer DC, Chesnut CH III, et al. Clinical use of biochemical markers of bone remodeling: Current status and future directions. Osteopor Int. 2000;11:467-480.
38. Meunier PJ, Delmas PD, Eastell R, et al. Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Therap. 1999;21:1025-1044.
39. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem. 1999;45:1359-1368.
40. Witts NB, Becker P. Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate. Bone. 1999;24:65-68.
41. Bjarnason NH, Sarkar S, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteopor Int. 2001;12:922-930.
42. Delmas PD, Recker RR, Chesnut CH III, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study. Osteopor Int. 2004;15:792-798.
43. Garnero P, Stevens RE, Ayres SA, et al. Short-term effects of new synthetic conjugated estrogens on biochemical markers of bone turnover. J Clin Pharmacol. 2002;42:290-296.
44. Rosen HN, Moses AC, Garber J, et al. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Intern. 1998;63:363-368.
45. Sornay-Rendu E, Garnero P, Munoz F, et al. Effect of withdrawal of hormone replacement therapy on bone mass and bone turnover: The OFELY study. Bone. 2003;33:159-166.
46. Hannon R, Blumsohn A, Naylor K, et al. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res. 1998;13:1124-1133.
47. Rosen HN, Moses AC, Garber J, et al. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Intern. 2000;66:100-103.
48. Worsfold M, Powell DE, Jones TJ, et al. Assessment of urinary bone markers for monitoring treatment of osteoporosis. Clin Chem. 2004;50:2263-2270.
49. Vesper HW, Smith SJ, Audain C, et al. Comparison study of urinary pyridinoline and deoxypyridinoline measurements in 13 US laboratories. Clin Chem. 2001;47:2029-2031.
50. Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem. 2001;47:694-702.
51. Ju HS, Leung S, Brown B, et al. Comparison of analytical performance and biological variability of three bone resorption assays. Clin Chem. 1997;43:1570-1576.
52. Masters PW, Jones RG, Purves DA, et al. Commercial assays for serum osteocalcin give clinically discordant results. Clin Chem. 1994;40:358-363.
53. Vesper HW, Demers LM, Eastell R, et al. Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline. Clin Chem. 2002;48:220-235.
54. Gorai I, Taguchi Y, Chaki O, et al. Specific changes of urinary excretion of cross-linked N-telopeptides of type I collagen in pre- and postmenopausal women: Correlation with other markers of bone turnover. Calcif Tissue Intern. 1997;60:317-322.
55. Marowska J, Kobylinska M, Lukaszkiewicz J, et al. Pyridinium crosslinks of collagen as a marker of bone resorption rates in children and adolescents: Normal values and clinical application. Bone. 1996;19:669-677.
56. Ohishi T, Takahashi M, Kawana K, et al. Age-related changes of urinary pyridinoline and deoxypyridinoline in Japanese subjects. Clin Invest Med. 1993;16:319-325.
57. Rauch F, Schonau E, Woitge H, et al. Urinary excretion of hydroxypyridinium cross-links of collagen reflects skeletal growth velocity in normal children. Exp Clin Endocrinol. 1994;102:94-97.
58. Rauch F, Rauch R, Woitge HW, et al. Urinary immunoreactive deoxypyridinoline in children and adolescents: Variations with age, sex and growth velocity. Scand J Clin Lab Invest. 1996;56:715-719.
59. Rauch F, Middelmann B, Rosmalen F, et al. Free deoxypyridinoline in urine and serum-results in children and adolescents. Exp Clin Endocrinol Diabet. 1996;104:396-399.
60. Shaw NJ, Dutton J, Fraser WD, et al. Urinary pyridinoline and deoxypyridinoline excretion in children. Clin Endocrinol. 1995;42:607-612.
61. Szulc P, Seeman E, Delmas PD. Biochemical measurements of bone turnover in children and adolescents. Osteopor Int. 2000;11:281-294.
62. Szulc P, Delmas PD. Biochemical markers of bone turnover in men. Calcif Tissue Intern. 2001;69:229-234.
63. Ingle BM, Hay SM, Bottjer HM, et al. Changes in bone mass and bone turnover following distal forearm fracture. Osteopor Int. 1999;10:399-407.
64. Ingle BM, Hay SM, Bottjer HM, et al. Changes in bone mass and bone turnover following ankle fracture. Osteopor Intern. 1999;10:408-415.
65. Naylor KE, Iqbal P, Fledelius C, et al. The effect of pregnancy on bone density and bone turnover. J Bone Miner Res. 2000;15:129-137.
66. Zerwekh JE, Ruml LA, Gottschalk F, et al. The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects. J Bone Miner Res. 1998;13:1594-1601.
67. Douglas AS, Miller MH, Reid DM, et al. Seasonal differences in biochemical parameters of bone remodeling. J Clin Pathol. 1996;49:284-289.
68. Perry HM, Horowitz M, Fleming S, et al. The effects of season and alcohol intake on mineral metabolism in men. Alcoholism. 1999;23:214-219.
69. Thomsen K, Eriksen EF, Jorgensen JC, et al. Seasonal variation of serum bone GLA protein. Scand J Clin Lab Invest. 1989;49:605-611.
70. Vanderschueren D, Gevers G, Dequeker J, et al. Seasonal variation in bone metabolism in young healthy subjects. Calcif Tissue Intern. 1991;49:84-89.
71. Woitge HW, Scheidt-Nave C, Kissling C, et al. Seasonal variation of biochemical indexes of bone turnover: Results of a population-based study. J Clin Endocrinol Metabol. 1998;83:68-75.
72. Fohr B, Dunstan CR, Seibel MJ. Markers of bone remodeling in metatstatic bone disease. J Clin Endocrinol Metabol. 2003;43:5059-5075.
73. Garnero P, Rousseau JC, Delmas PD. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthrit Rheumatol. 2000;43:953-968.
74. Robins SP, Stewart P, Astbury C, et al. Measurement of the cross linking compound, pyridinoline, in urine as an index of collagen degradation in joint disease. Ann Rheumatol Dis. 1986;45:969-973.
75. Naylor KE, Jackson B, Eastell R. The renal clearance of free and peptide-bound deoxypyridinoline: Response to pamidronate treatment of Paget's disease. J Bone Miner Res. 2003;18:658-661.
76. Ginty F, Flynn A, Cashman K. Inter and intra-individual variations in urinary excretion of pyridinium crosslinks of collagen in healthy young adults. European J Clin Nutr. 1998;52:71-73.
77. Woitge HW, Pecherstorfer M, Li Y, et al. Novel serum markers of bone resorption: Clinical assessment and comparison with established urinary indices. J Bone Miner Res. 1999;14:792-801.
78. Seibel MJ, Lang M, Geilenkeuser WJ. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem. 2001;47:1443-1450.
79. Chesnut CH III. Sources of biological bone marker variability. Bone markers: Biochemical and Clinical Perspectives. Eastell R, Baumann M, Hoyle NR eds., London: Martin Dunitz Ltd;2001:119-121.